Keros Therapeutics announced an agreement with Massachusetts General Hospital for the design of a Phase 2 clinical trial of rinvatercept in ALS patients within the HEALEY ALS MyMatch program. The company also presented additional Phase 1 data from rinvatercept in healthy volunteers and preclinical data at the 2026 Muscular Dystrophy Association Conference.
Key takeaways
Entered agreement with Massachusetts General Hospital on March 9, 2026, for Phase 2 trial design of rinvatercept in ALS within HEALEY ALS MyMatch program led by Sean M. Healey & AMG Center for ALS at Mass General Brigham.
Presented additional proteome analysis data from Phase 1 trial of rinvatercept (KER-065) in healthy volunteers at 2026 MDA Clinical & Scientific Conference.
Phase 1 trial showed rinvatercept was generally well-tolerated with increases in muscle mass, decreases in fat mass, and increases in bone mineral density.
Proteomic data confirmed target engagement, anti-fibrotic and anti-inflammatory effects, and shifts in energy metabolism supporting muscle growth.
Preclinical data presented: rinvatercept improved muscle and bone mass/strength in D2.mdx mouse model of DMD and showed beneficial effects in ALS mouse model.
Press releases attached as Exhibits 99.1 and 99.2.